Dr. Bryan Curtin is a Board Certified gastroenterologist with specialized expertise in gastrointestinal (GI) motility disorders.
Knee replacement surgery is offered at Mercy Medical Center in Baltimore. The orthopedic team at Orthopedics and Joint Replacement at Mercy offer innovative technology for knee replacement surgery.
Cardiologists at The Heart Center at Mercy treat patients with heart conditions including heart attack, heart murmur and heart disease.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
The primary aim of the study is to determine whether the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread differs from a healthy, age-matched cohort of the American population. This is a collaborative study with the University of California, San Diego and Rob Knight, PhD who will perform the genetic analysis of bio-specimens from patients who undergo cytoreductive surgery with HIPEC. (Clinical Trials ID #: NCT02599116)
This study involves patients with mucinous peritoneal tumors, including pseudomyxoma peritonei (PMP), who are not candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or other potentially beneficial surgery.
An interventional radiologist will insert a percutaneous drain. The combination drug treatment of bromelain and acetylcysteine will be injected directly into the tumor or peritoneal cavity via drain and dwell for 24 hours. The aspiration/drainage and repeat drug treatments will be delivered via this drain. The dose of the drug is dependent on the calculated tumor dimensions and volume outlined in the protocol.
The expectation is that the drug combination will dissolve the tumor, allowing it to be drained. Remaining mucinous tumor that is unable to be drained will be considered for repeat drug treatments.
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
The purpose of this phase II trial is to determine the toxicity and post-operative complications related to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as an initial treatment option for patients with ovarian, fallopian tube, or primary peritoneal cancers and its impact on quality of life. Subjects will be randomized to one of two treatment groups: CRS with HIPEC followed by combination chemotherapy, carboplatin and paclitaxel, or CRS only followed by combination chemotherapy carboplatin and paclitaxel.
Protocol Title and ClinicalTrials ID#:
A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer. NCT02124421
This study is a phase II, open label, historical controlled study to determine the impact of antibiotic therapy on the disease progression and overall survival of the patients with Pseudomyxoma Peritonei (PMP). The study will examine the use of the antibiotic PREVPAC, in patients undergoing CRS/HIPEC for appendiceal neoplasms with peritoneal dissemination and its effect on patient outcomes and survival. (ClinicalTrials.gov ID#: NCT02387203)
This is a study to define the pathological staging for appendiceal neoplasms by examining mutations of the genetic makeup of tumor tissue and to analyze prognostic factors associated with various stages of appendiceal cancer with peritoneal dissemination.
This study involves storing specimens from CRS/HIPEC patients with advanced colorectal, gastric, small bowel, primary peritoneal, ovarian cancers, peritoneal mesothelioma, and sarcomas. The purpose is to collect, maintain, and store tissues specimens from CRS/HIPEC and clinical data for future research. The collection of clinical data and outcomes from CRS/HIPEC for advanced intra-abdominal cancers will be used to refine future treatment protocols and enhance patient care.
Surgical Oncology at Mercy Medical Center in Baltimore, Maryland, treats a broad range of cancers and benign tumors including colon and rectal cancer, liver cancer, pancreatic cancer, thyroid cancer, sarcoma and melanoma. Drs. Armando Sardi, Vadim Gushchin and Kurtis Campbell utilize modern medical technologies such as laparoscopy, brachytherapy, hyperthermic intraperitoneal chemotherapy (HIPEC) and radiofrequency ablation to help eliminate tumors with minimal damage to healthy tissue.
Surgical Oncology is part of The Institute for Cancer Care at Mercy Medical Center.
Dr. Kurtis Campbell is a Board Certified cancer surgeon who provides expertise in a variety of procedures including HIPEC for peritoneal carcinomatosis as well as the Whipple procedure to treat pancreatic disease.